Zhejiang Cancer Hospital, Hangzhou 310022, China.
Hangzhou Institute of Medicine (HIM), Chinese Academy of Sciences, Hangzhou 310018, China.
Biomolecules. 2024 Mar 12;14(3):342. doi: 10.3390/biom14030342.
Protein phosphatases are primarily responsible for dephosphorylation modification within signal transduction pathways. Phosphatase of regenerating liver-3 (PRL-3) is a dual-specific phosphatase implicated in cancer pathogenesis. Understanding PRL-3's intricate functions and developing targeted therapies is crucial for advancing cancer treatment. This review highlights its regulatory mechanisms, expression patterns, and multifaceted roles in cancer progression. PRL-3's involvement in proliferation, migration, invasion, metastasis, angiogenesis, and drug resistance is discussed. Regulatory mechanisms encompass transcriptional control, alternative splicing, and post-translational modifications. PRL-3 exhibits selective expressions in specific cancer types, making it a potential target for therapy. Despite advances in small molecule inhibitors, further research is needed for clinical application. PRL-3-zumab, a humanized antibody, shows promise in preclinical studies and clinical trials. Our review summarizes the current understanding of the cancer-related cellular function of PRL-3, its prognostic value, and the research progress of therapeutic inhibitors.
蛋白磷酸酶主要负责信号转导途径中的去磷酸化修饰。肝再生磷酸酶-3(PRL-3)是一种双特异性磷酸酶,与癌症的发病机制有关。了解 PRL-3 复杂的功能并开发靶向治疗方法对于推进癌症治疗至关重要。本综述强调了其调节机制、表达模式以及在癌症进展中的多方面作用。讨论了 PRL-3 在增殖、迁移、侵袭、转移、血管生成和耐药性中的作用。调节机制包括转录控制、选择性剪接和翻译后修饰。PRL-3 在特定癌症类型中表现出选择性表达,使其成为治疗的潜在靶点。尽管小分子抑制剂取得了进展,但仍需要进一步研究以实现临床应用。PRL-3-zumab 是一种人源化抗体,在临床前研究和临床试验中显示出前景。我们的综述总结了目前对 PRL-3 与癌症相关的细胞功能、预后价值以及治疗抑制剂研究进展的理解。